VYKAT XR (Diazoxide Choline) Patent Expiration, LOE Window & CMS Spending
VYKAT XR (Diazoxide Choline) by Neurocrine Biosciences: FDA Orange Book core substance LOE 2029-03-05 (last listed 2035-11-12), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $26,640 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Neurocrine Biosciences |
| FDA Application & Pathway | N216665 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2029-03-05 |
| Last Listed Patent or Exclusivity Date | 2035-11-12 |
| Orange Book Patents (*PED Extensions) | 18 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($26,640 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Neurocrine Biosciences across sibling Meru public-data platforms.